CN116348107A - 通过肾脏保护来治疗癌症的方法 - Google Patents

通过肾脏保护来治疗癌症的方法 Download PDF

Info

Publication number
CN116348107A
CN116348107A CN202180070528.4A CN202180070528A CN116348107A CN 116348107 A CN116348107 A CN 116348107A CN 202180070528 A CN202180070528 A CN 202180070528A CN 116348107 A CN116348107 A CN 116348107A
Authority
CN
China
Prior art keywords
iron
content
protoporphyrin
hepcidin
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180070528.4A
Other languages
English (en)
Chinese (zh)
Inventor
D·凯泽
A·吉列姆
R·扎格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renibus Therapeutics Inc
Original Assignee
Renibus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renibus Therapeutics Inc filed Critical Renibus Therapeutics Inc
Publication of CN116348107A publication Critical patent/CN116348107A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180070528.4A 2020-09-11 2021-09-13 通过肾脏保护来治疗癌症的方法 Pending CN116348107A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062706829P 2020-09-11 2020-09-11
US62/706,829 2020-09-11
US202163158803P 2021-03-09 2021-03-09
US63/158,803 2021-03-09
PCT/US2021/050064 WO2022056378A1 (en) 2020-09-11 2021-09-13 Method for treating cancer with kidney protection

Publications (1)

Publication Number Publication Date
CN116348107A true CN116348107A (zh) 2023-06-27

Family

ID=80626052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180070528.4A Pending CN116348107A (zh) 2020-09-11 2021-09-13 通过肾脏保护来治疗癌症的方法

Country Status (10)

Country Link
US (1) US20220079984A1 (https=)
EP (1) EP4210691A4 (https=)
JP (1) JP2023541606A (https=)
KR (1) KR20230112608A (https=)
CN (1) CN116348107A (https=)
AU (1) AU2021342291A1 (https=)
CA (1) CA3192411A1 (https=)
IL (1) IL301305A (https=)
MX (1) MX2023002929A (https=)
WO (1) WO2022056378A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118103047A (zh) 2021-08-27 2024-05-28 美国瑞根特有限公司 铁组合物及其制备和使用方法
JPWO2024253189A1 (https=) * 2023-06-09 2024-12-12

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200277325A1 (en) * 2019-02-28 2020-09-03 Renibus Therapeutics, Inc. Novel iron compositions and methods of making and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651758B2 (en) * 1992-02-07 1994-07-28 Tsumura & Co. Side-effect alleviant
AU6010696A (en) * 1995-06-10 1997-01-09 Vitra Pharmaceuticals Ltd Iron compounds, compositions, methods of making the same and uses thereof
WO2005094202A2 (en) * 2004-03-16 2005-10-13 Navinta, Llc Iron sucrose complexes and method of manufacture thereof
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
SI3200582T1 (sl) * 2014-09-29 2024-04-30 Fred Hutchinson Cancer Center Sestave, kompleti in metode za indukcijo pridobljene citorezistence z uporabo induktorjev stresnih proteinov
AU2016366668A1 (en) * 2015-12-11 2018-05-31 Fred Hutchinson Cancer Research Center Peptides for renal therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200277325A1 (en) * 2019-02-28 2020-09-03 Renibus Therapeutics, Inc. Novel iron compositions and methods of making and using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZAGER RA，等: "Combined iron sucrose and protoporphyrin treatment protects against ischemic and toxin-mediated acute renal failure", KIDNEY INT, vol. 90, no. 1, 24 March 2016 (2016-03-24), pages 3 - 4 *
ZAGER RA，等: "Iron sucrose (\'RBT-3\') activates the hepatic and renal HAMP1 gene, evoking renal hepcidin loading and resistance to cisplatin nephrotoxicity", NEPHROL DIAL TRANSPLANT, vol. 36, no. 3, 2 December 2020 (2020-12-02) *

Also Published As

Publication number Publication date
IL301305A (en) 2023-05-01
EP4210691A4 (en) 2025-02-26
MX2023002929A (es) 2023-05-22
BR112023004583A2 (pt) 2023-04-11
WO2022056378A1 (en) 2022-03-17
AU2021342291A1 (en) 2023-04-20
JP2023541606A (ja) 2023-10-03
EP4210691A1 (en) 2023-07-19
US20220079984A1 (en) 2022-03-17
KR20230112608A (ko) 2023-07-27
CA3192411A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
EP3204413B1 (en) Carrier-antibody compositions and methods of making and using the same
US20050070607A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
JP6894837B2 (ja) ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法
US20140120081A1 (en) Use of carbon nanomaterials with antioxidant properties to treat oxidative stress
CN116348107A (zh) 通过肾脏保护来治疗癌症的方法
US20250011470A1 (en) Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
Shiels et al. Pharmacokinetics of bilirubin-10-sulfonate and biliverdin in the rat
Yuan et al. Anticoagulant therapy without bleeding: A novel molybdenum‐based nanodots alleviate lethal coagulation in bacterial sepsis by inhibiting ROS‐facilitated caspase‐11 activation
KR102444113B1 (ko) 안정한 글루코코르티코이드 제제
WO2021263281A2 (en) Methods and compositions for the treatment of covid-19 and associated respiratory distress and multi-organ failure, sepsis, acute respiratory distress syndrome, and cordiovascular diseases
HK40095700A (zh) 通过肾脏保护来治疗癌症的方法
Li et al. Sodium selenosulfate at an innocuous dose markedly prevents cisplatin-induced gastrointestinal toxicity
BR112023004583B1 (pt) Uso de uma composição farmacêutica com uma quantidade de composição de sacarose de ferro para proteger o rim durante a quimioterapia do câncer e durante imageamento de radiocontraste
US20060009496A1 (en) Method for preventing hemoprotein and heme-mediated lipid peroxidation
Obeid et al. Advanced glycation end products overload might explain intracellular cobalamin deficiency in renal dysfunction, diabetes and aging
Kadir et al. Attenuation of cisplatin-induced acute kidney injury by N-(2-Hydroxyphenyl) acetamide and its gold conjugated nano-formulations in mice.
CN116801733A (zh) 用于在慢性炎症性病症中靶向晚期糖基化终产物受体(rage)的组合物
WO2017165692A1 (en) Compounds linked with a saccharide metal complex and uses thereof
US20120010144A1 (en) Peg-albumin composition having at least one protected thiol region as a platform for medications
Oliveira N-Acetylcysteine (NAC): Impacts on Human Health
Yao et al. Oral Tea Polyphenol Nanoparticles for Targeted Therapy of Ulcerative Colitis: Enhanced Anti-inflammatory and Antioxidant Effects
Zhao et al. Drug-reinforced metal-organic framework nanozyme for combined treatment of ischemia/reperfusion acute kidney injury
Jin et al. Nano‐networks via reaction‐induced self‐assembly coordinate spatiotemporal multi‐drug delivery for acute kidney injury therapy
CN110139673B (zh) 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn
TW201632189A (zh) 含單醣及/或多醣作為有效成份的醫藥組合物及單醣及/或多醣的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095700

Country of ref document: HK